MAT2B

Across TCGA pan-cancer cohorts, MAT2B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MAT2B data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MAT2B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MAT2B expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where MAT2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.928	0.128	.014	30	view →
HNSC	DFS	Tertile	All	0.693	0.875	.019	4	view →
LUAD	OS	Median	III,IV	0.439	0.794	.020	3	view →
LSCC	DFS	Quartile	All	1.000	0.558	.026	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MAT2B–CCRCC (DFS)

Open the CCRCC breakdown →